Tool Measures Patient Health, Well-Being After Radionuclide Therapy

By News Release


Moffitt Cancer Center researchers have developed a tool to determine how radionuclide therapy (RNT) for prostate cancer impacts patient-reported outcomes with the goal of using this information to guide treatment and improve quality of care. Their findings have been published in The Journal of Nuclear Medicine.

The use of patient-reported outcomes allows patients, caregivers and clinicians to better understand how cancer and its treatment impact quality of life, making cancer care more patient-oriented. The data are measured using patient questionnaires that focus on cancer symptoms, side effects of treatment, and social and emotional well-being. The US Food & Drug Administration encourages the addition of patient-reported outcomes measures in clinical trials. These measures are being incorporated into clinical practice, and results are being used to guide clinical decision-making and treatment planning.  

The Moffitt team wanted to determine how a new type of therapy for patients with advanced prostate cancer affects quality of life. RNT is a new type of radiation therapy that links a radioactive chemical, called a radionuclide, to a cancer patients and has side effects that differ from standard therapy, Moffitt researchers wanted to understand which patient-reported outcomes are most influential for patients receiving RNT.

Moffitt researchers set out to develop a new patient-reported outcomes questionnaire that could accurately identify the key symptoms and side effects experienced by prostate cancer patients receiving RNT. Researchers reviewed the literature of published RNT clinical trials to create a list of symptoms and side effects associated with RNT. The research team also interviewed prostate cancer patients, caregivers, and clinicians to identify the most concerning symptoms and side effects.

“We were thorough in determining which symptoms and side effects are important to patients receiving RNT for prostate cancer,” said Lisa M Gudenkauf, PhD, lead study author and research scientist in the Department of Health Outcomes and Behavior at Moffitt.

Their questionnaire, called the Functional Assessment of Cancer Therapy–Radionuclide Therapy (FACT-RNT), includes 15 questions to identify symptoms and side effects associated with RNT, such as dry mouth, nausea, loss of appetite, bone pain, fatigue and feelings of isolation due to illness/treatment.

The Moffitt research team hopes this newly developed assessment tool will help patients, their caregivers, and clinicians understand the effects of RNT, improve patient outcomes, and lead to more patient-centered care.

“The FACT-RNT will help future researchers better understand the impact of RNT and other therapies on quality of life in patients with prostate cancer,” explained Brian Gonzalez, PhD, senior study author and associate member of the Department of Health Outcomes and Behavior at Moffitt.

Back To Top

Tool Measures Patient Health, Well-Being After Radionuclide Therapy.  Appl Rad Oncol. 

By News Release| January 24, 2023

About the Author

News Release

News Release

Copyright © Anderson Publishing, Ltd

    Agility CMS